Yakes, F Michael <br/><br/>
Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.  [electronic resource] 

 -  Molecular cancer therapeutics  Dec 2011 
 - 2298-308 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1538-8514 
<br/><br/><label>Standard No.: </label>10.1158/1535-7163.MCT-11-0264  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Angiogenesis Inhibitors--pharmacology<br/>Anilides--pharmacology<br/>Animals<br/>Cell Growth Processes--drug effects<br/>Cell Line, Tumor<br/>Drug Evaluation, Preclinical<br/>Female<br/>Humans<br/>Mice<br/>Mice, Nude<br/>Models, Biological<br/>Neoplasm Metastasis--prevention & control<br/>Neoplasms--drug therapy<br/>Neovascularization, Pathologic--drug therapy<br/>Protein Kinase Inhibitors--pharmacology<br/>Proto-Oncogene Proteins c-met--antagonists & inhibitors<br/>Pyridines--pharmacology<br/>Vascular Endothelial Growth Factor Receptor-2--antagonists & inhibitors